The strong early efficacy data across multiple tumor types, including in KRASi-experienced patients, significantly de-risks darlifarnib as a combination partner. Traders should watch for the ASCO presentation on May 30 and the investor event on June 3 for further details and potential partnership or development updates. The stock may see positive momentum, but given the early stage, volatility around these events is expected.
KURA drugs
KURA drug pipeline →How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 26 $10.41entry
- T+1 · 6mo ago −1.63%α −1.65% · $10.24
- T+5 · 6mo ago −13.83%α −15.05% · $8.97
- T+20 · 5mo ago +2.69%α +4.64% · $10.69
- T+60 · 3mo ago +20.36%α +17.64% · $12.53
Price Chart
How similar events traded
Executive Summary
Kura Oncology reported positive first-in-human Phase 1a data for darlifarnib plus adagrasib in KRAS G12C-mutated solid tumors, showing tumor shrinkage in 77% of evaluable patients and ORRs of 67% in PDAC, 50% in NSCLC, and 29% in KRASi-naïve CRC. The data provide clinical proof-of-mechanism for targeting the mTORC1-RHEB resistance pathway, positioning darlifarnib as a potential combination partner for KRAS inhibitors. The results are being presented at ASCO 2026 and a virtual investor event is scheduled for June 3.
Key Facts
- Tumor shrinkage observed in 77% (20/26) of response-evaluable patients across PDAC, NSCLC, and CRC.
- ORR of 67% in PDAC, 50% in NSCLC, and 29% in KRASi-naïve CRC.
- Clinical activity seen in heavily pretreated patients, including those with prior KRAS inhibitor exposure.
- Combination was well tolerated with a manageable safety profile; 37% of patients remained on study at data cutoff (March 25, 2026).
- Data to be presented at ASCO 2026 on May 30; virtual investor event on June 3, 2026.
Financial Impact
No financial figures provided; early-stage clinical data with no revenue or guidance impact.
Risk Factors
- Phase 1a data is early-stage; larger trials may not replicate these results.
- Competition from other KRAS inhibitor combinations and resistance mechanisms.
- Darlifarnib 8 mg dose discontinued in this combination, indicating dose-limiting toxicity or lack of benefit at that level.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3300885 |
Track record
29 reports on KURA
5 of 8 bullish or bearish reports moved the stock their way by T+60. Best: +52.28% at T+60 after the Jun 3, 2026 report. 9 of 13 went positive at some point.
Filters
- Nov 16, 2026today Insider Buy Bullish 5/10 Entry $7.15 Now $7.09 −0.84% settles Feb 16
- Nov 16, 2026today 144 Neutral 3/10 Entry $7.15 Now $7.09 −0.84% settles Feb 16
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $7.15 Now $7.09 −0.84% settles Feb 16
- Nov 10, 20266d ago S-3ASR Neutral 4/10 Entry $7.73 Now $7.09 −8.28% settles Feb 9
- Nov 10, 20266d ago Press Release Neutral 5/10 Entry $7.73 Now $7.09 −8.28% settles Feb 9
- Nov 4, 202612d ago Press Release Neutral 4/10 Entry $7.61 Now $7.09 −6.83% settles Feb 2
- Sep 29, 20266w ago Insider Cluster Bearish 5/10 Entry $10.71 Now $7.09 +33.80% settles Dec 24
- Sep 29, 20266w ago Press Release Bullish 6/10 Entry $10.81 Now $7.09 −34.38% settles Dec 23
- Sep 9, 20269w ago 8-K Bullish 6/10 Entry $12.09 Now $7.09 −41.36% settles Dec 3
- Sep 8, 20269w ago 8-K Neutral 2/10 Entry $12.52 Now $7.09 −43.37% settles Dec 2
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers